| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* University of Edinburgh, Institute of Immunology and Infection Research, School of Biological Sciences, Edinburgh, United Kingdom;
Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences, Bristol, United Kingdom; and
University of Edinburgh, Centre for Inflammation Research and Centre for Multiple Sclerosis Research, Queen’s Medical Research Institute, Edinburgh, U.K.
It has recently been proposed that experimental autoimmune encephalomyelitis, once considered the classical Th1 disease, is predominantly Th17 driven. In this study we show that myelin-reactive Th1 preparations devoid of contaminating IL-17+ cells are highly pathogenic. In contrast, Th17 preparations lacking IFN-
+ cells do not cause disease. Our key observation is that only Th1 cells can access the noninflamed CNS. Once Th1 cells establish the experimental autoimmune encephalomyelitis lesion, Th17 cells appear in the CNS. These data shed important new light on the ability of Th1 vs Th17 cells to access inflamed vs normal tissue. Because the IL-17-triggered release of chemokines by stromal cells could attract many other immune cells, allowing Th17 cells to access the tissues only under conditions of inflammation may be a key process limiting (auto)immune pathology. This has major implications for the design of therapeutic interventions, many of which are now aiming at Th17 rather than Th1 cells.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by grants form the Medical Research Council (U.K.) and the Wellcome Trust. C.A.S. is supported by the Batchworth Trust. S.M.A. is a Medical Research Council Senior Research Fellow and a Research Councils U.K. Fellow in Translational Medicine.
2 C.T.P., C.A.S., and C.W.Z.L. contributed equally to this study.
3 Address correspondence and reprint requests to Dr. Stephen M. Anderton, University of Edinburgh, Ashworth Laboratories, Kings Buildings, West Mains Road, Edinburgh EH9 3JT, U.K. E-mail address: steve.anderton{at}ed.ac.uk
4 Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; Ac, acetylated; MBP, myelin basic protein; pMOG, myelin oligodendrocyte glycoprotein peptide.
This article has been cited by other articles:
|
|
 |
|
  G. Shi, M. Ramaswamy, B. P. Vistica, C. A. Cox, C. Tan, E. F. Wawrousek, R. M. Siegel, and I. Gery Unlike Th1, Th17 Cells Mediate Sustained Autoimmune Inflammation and Are Highly Resistant to Restimulation-Induced Cell Death J. Immunol., December 1, 2009; 183(11): 7547 - 7556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes J. Immunol., December 1, 2009; 183(11): 7169 - 7177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Canonigo-Balancio, C. Fos, T. Prod'homme, S. Becart, and A. Altman SLAT/Def6 Plays a Critical Role in the Development of Th17 Cell-Mediated Experimental Autoimmune Encephalomyelitis J. Immunol., December 1, 2009; 183(11): 7259 - 7267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Oyamada, H. Ikebe, M. Itsumi, H. Saiwai, S. Okada, K. Shimoda, Y. Iwakura, K. I. Nakayama, Y. Iwamoto, Y. Yoshikai, et al. Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis J. Immunol., December 1, 2009; 183(11): 7539 - 7546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Brereton, C. E. Sutton, S. J. Lalor, E. C. Lavelle, and K. H. G. Mills Inhibition of ERK MAPK Suppresses IL-23- and IL-1-Driven IL-17 Production and Attenuates Autoimmune Disease J. Immunol., August 1, 2009; 183(3): 1715 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Walsh, M. T. Brady, C. M. Finlay, L. Boon, and K. H. G. Mills Infection with a Helminth Parasite Attenuates Autoimmunity through TGF-{beta}-Mediated Suppression of Th17 and Th1 Responses J. Immunol., August 1, 2009; 183(3): 1577 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vojdani, J. Lambert, and G. Kellermann The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep064v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jin, X.-F. Zhou, J. Yu, X. Cheng, and S.-C. Sun Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK Blood, June 25, 2009; 113(26): 6603 - 6610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Ingram, J. D. Isaacs, G. Kaur, D. E. Lowther, C. J. Reynolds, R. J. Boyton, J. Collinge, G. S. Jackson, and D. M. Altmann A role of cellular prion protein in programming T-cell cytokine responses in disease FASEB J, June 1, 2009; 23(6): 1672 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Louvet, B. G. Kabre, D. W. Davini, N. Martinier, M. A. Su, J. J. DeVoss, W. L. Rosenthal, M. S. Anderson, H. Bour-Jordan, and J. A. Bluestone A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy J. Exp. Med., March 16, 2009; 206(3): 507 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wasserfall and M. A. Atkinson Taking a Daily Vitamin to Prevent Type 1 Diabetes? Diabetes, January 1, 2009; 58(1): 24 - 25. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Ramos, J. B. Hernandez, M. Gatzka, and C. M. Walsh Enhanced T Cell Apoptosis within Drak2-Deficient Mice Promotes Resistance to Autoimmunity J. Immunol., December 1, 2008; 181(11): 7606 - 7616. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
